FONTANA Trial at ESMO 2026: Torvutatug Samrotecan Shows 56.6% Response Rate in Platinum-Resistant Ovarian Cancer
FONTANA Trial at ESMO 2026: Torvutatug Samrotecan Shows 56.6% Response Rate in Platinum-Resistant Ovarian Cancer Oncodaily
1636 материалов по теме, собраны автоматически из проверенных источников
FONTANA Trial at ESMO 2026: Torvutatug Samrotecan Shows 56.6% Response Rate in Platinum-Resistant Ovarian Cancer Oncodaily
Крупное исследование не подтвердило связь переработанной пищи с раком кишечника - NEWSru.co.il NEWSru.co.il
Two cancer researchers receive esteemed $500K Albany Prize NEWS10 ABC
Лекарство от онкологии уже в вашем теле — исследование ученых, которое поможет победить рак поджелудочной ФОНТАНКА.ру
Merck and Moderna release promising data on cancer vaccine trial NPR
New research indicates that commonly used measures of kidney function underestimate the prevalence of chronic kidney disease (CKD) in patients with cancer. The findings will be presented at ASN Kidney Week 2026, Oct. 22–25.
Celebrating 8 Community Members Elected to the National Academy of Medicine - The Mark Foundation for Cancer Research Oncodaily
Patient-Friendly Research Summaries Spotlight Advances in Pancreatic Cancer The ASCO Post
Case CCC Receives Support from Children’s Tumor Foundation and Gateway for Cancer Research for Rare Cancer Treatment Trial Case Western Reserve University
Nikita Wagle: Advancing Health Equity Through Cancer Disparities Research Oncodaily
Growing Awareness and Funding Cancer Research Through No Shave November – NFCR Oncodaily
A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different RAS mutations and those without an identified RAS mutation.
How Israeli Researchers Are Using AI To Transform Cancer Treatment and Diagnoses Baltimore Jewish Times
What if we could use a cancer's own byproduct to make drugs that destroy tumor cells from the inside? That is what Katsunori Tanaka and his team have done at the RIKEN Pioneering Research Institute (PRI) in Japan.
ИИ научился определять риск рака через популярное фото - исследование Cursorinfo